Aquestive Therapeutics: Fourth Quarter Financial Results Overview

Aquestive Therapeutics Inc. Reports Fourth Quarter Financial Results

Aquestive Therapeutics Inc., headquartered in Warren, New Jersey, announced on Wednesday that it recorded a net loss of $31.9 million for the fourth quarter.

The company’s quarterly loss translated to 26 cents per share.

These figures fell short of analyst projections, as the consensus from five Zacks Investment Research analysts anticipated a loss of only 13 cents per share.

Quarterly revenue reached $13 million, which was also below expectations. Analysts had forecasted revenue of $13.4 million for the period.

For the full year, Aquestive Therapeutics reported an increased net loss totaling $83.8 million, or 78 cents per share. Annual revenue amounted to $44.5 million.

At the close of trading on Wednesday, the company’s stock was priced at $4.35 per share, compared to $2.73 per share one year earlier.